ATG5 and breast carcinoma: Therefore, HSP90AA1 and ATG5 in our model may have the potential to be used as biomarkers for early diagnosis and prognostic assessment of breast cancer patients, and by detecting their expression it may be possible to monitor the dynamic progression of breast cancer and assess the effect of immunotherapy in breast cancer patients.